AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Oceania Healthcare Limited (ASX:OCA)
Robust Growth in Financial Results: Oceania Healthcare Limited (ASX:OCA) generated NPAT or Net profit after tax amounting to $77 million in FY 2018 which implies the YoY growth of 71.5%. The company also saw a rise in the total assets at the end of FY 2018 on the back of acquisition of Greenfield and revaluations as well as capital development program. The company has also enhanced the debt facilities in the month of July 2018 to fulfill its ongoing developments as well as operations.
The company has witnessed a decline in the total expenses from $184.6 million in FY 2017 to $176.4 million in FY 2018. However, the company witnessed a rise in the operating revenues from $171.8 million in FY 2017 to $180 million in FY 2018. Â
The management of the company reflected favourable views regarding the outlook about the companyâs performance. The management has maintained its focus towards working for robust growth momentum and they are positive in regard to the brownfields pipeline.
Telix Pharmaceuticals Limited (ASX:TLX)
Working towards Japan footprint: Telix Pharmaceuticals Limited (ASX:TLX) got listed on the Australian Securities Exchange or ASX in November 2017. The current market price of the company is A$0.625 per share (as on December 05, 2018). The current market capitalization of Telix Pharmaceuticals stood at $135.86 million, and the stock price of the company is trading towards the lower range. The company had earlier made an announcement that it had established Telix Pharma Japan KK and this was done so that the operations in Japan as well as to make a presence in that country. It seems like the company is optimistic about the Japanese market.
From the past few months, the company has been delivering negative returns. In the previous six months and three months, it has delivered the return of -5.88% and -30.43%, respectively.
Visioneering Technologies, Inc (ASX:VTI)
Subdued Performance of the Stock: Visioneering Technologies, Inc (ASX:VTI) got listed on Australian Securities Exchange or ASX in the month of March 2017. At the time of writing, the stock price of the company is trading at A$0.165 per share. The market capitalization of the company stands at $42.21 million. The stock price of the company is trading towards the lower range. From the past few months, the stock has been delivering negative returns.
Over the past six months, the stock has delivered the return of -52.78% while in the past three months it has given -2.86% return. However, in the past one month, the stock delivered the return of -5.56%. The company ended Q3 2018 with the net revenues amounting to US$1.06 million which implies the growth of 75% on the quarter-over-quarter basis.
Smiles Inclusive Limited (ASX:SIL)
Look at returns from past few months: On Australian Securities Exchange or ASX, Smiles Inclusive Limited (ASX:SIL) was listed in the month of April 2018. The company ended the trading session on December 5, 2018, with the market price of A$0.355 per share. However, the stock price of the company is trading towards the lower range, and the companyâs market capitalization stood at $21.44 million. Earlier, the company had provided EBITDA as well as NPAT numbers for FY 2019. As per the management, in FY 2019, the company is expected to garner NPAT amounting to $2.3 million while it is expected to generate EBITDA amounting to $5 million in the same period.
Over the past three months and six months, the stock has delivered the return of -65.26% and -62.63%, respectively.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
